1. 4th International Kyoto Liver Cancer Symposium: Emerging Strategies to ...
May 21, 2014 · Dr. Ryosuke Tateishi has been working on hepatocellular carcinoma (HCC) since 1998 when he started his PhD in Hepatology at the University of ...
. 2014 May 21;3(2):133–281. doi: 10.1159/000343869
2. Tomoki Nakano Age, Birthday, Zodiac Sign and Birth Chart
Born on December 19, 1975, Tomoki Nakano is 48 years old. Zodiac sign is Sagittarius. Life path number is 8. Analyze Tomoki Nakano birth chart and kundli.
3. Dental implants in oral rehabilitation of a maxillary cancer ...
Dental implants in oral rehabilitation of a maxillary cancer reconstruction: A case report. Tomoki Sumida, Hiroyuki Nakano, Hiroyuki Hamakawa, Yoshihide Mori.
This output contributes to the following UN Sustainable Development Goals (SDGs)
4. The clinical outcome of pazopanib treatment in Japanese patients with ...
The authors investigated the efficacy and safety of pazopanib in 156 Japanese patients with relapsed STS. This was a retrospective study based on the ...
Because the efficacy and safety of pazopanib in Japanese patients with soft tissue sarcoma (STS) had not been evaluated previously in a large‐scale cohort, the authors investigated the efficacy and safety of pazopanib in 156 Japanese patients with ...
See AlsoWhen Is A Case Of You (2013) Set
5. Lactiplantibacillus plantarum 06CC2 Enhanced the Expression of ... - MDPI
LP06CC2 treatment enhanced the expression of intestinal ABCG2, thereby promoting the excretion of UA and other substances from the intestinal tract.
ATP-binding cassette transporter subfamily G member 2 (ABCG2) is responsible for the excretion of foreign substances, such as uric acid (UA) and indoxyl sulfate (IS), from the body. Given the importance of increased ABCG2 expression in UA excretion, we investigated the enhancement of intestinal ABCG2 expression using Lactiplantibacillus plantarum 06CC2 (LP06CC2). Mice were reared on a potassium oxonate-induced high-purine model at doses of 0.02% or 0.1% LP06CC2 for three weeks. Results showed that LP06CC2 feeding resulted in increased ABCG2 expression in the small intestine. The expression level of large intestinal ABCG2 also showed a tendency to increase, suggesting upregulation of the intestinal excretion transporter ABCG2 by LP06CC2. Overall, LP06CC2 treatment increased fecal UA excretion and showed a trend towards increased fecal excretion of IS, suggesting that LP06CC2 treatment enhanced the expression of intestinal ABCG2, thereby promoting the excretion of UA and other substances from the intestinal tract.
6. Genomic landscape of colitis-associated cancer indicates ...
Jan 2, 2018 · ... Tomoki Yamano, Akihiro Fujimoto, Mayuko Furuta, Kaoru Nakano, Aya ... cancer whereas RNF43-mutated CACs did not have this tendency. RNA ...
// Masashi Fujita 1 , Nagahide Matsubara 2 , Ikuo Matsuda 3 , Kazuhiro Maejima 1 , Ayako Oosawa 1 , Tomoki Yamano 2 , Akihiro Fujimoto 4 , Mayuko Furuta 1 , Kaoru Nakano 1 , Aya Oku-Sasaki 1 , Hiroko Tanaka 5 , Yuichi Shiraishi 5 , Raúl Nicolás Mateos 6, 7 , Kenta Nakai 6, 7 , Satoru Miyano 5 , Naohiro Tomita 2 , Seiichi Hirota 3 , Hiroki Ikeuchi 8 and Hidewaki Nakagawa 1 1 Laboratory for Genome Sequencing Analysis, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan 2 Division of Lower Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan 3 Department of Surgical Pathology, Hyogo College of Medicine, Nishinomiya, Japan 4 Department of Drug Discovery Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan 5 Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan 6 Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa-shi, Chiba, Japan 7 Laboratory of Functional Analysis in silico, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan 8 Department of Inflammatory Bowel Disease Surgery, Hyogo College of Medicine, Nishinomiya, Japan Correspondence to: Hidewaki Nakagawa, email: hidewaki@ims.u-tokyo.ac.jp Hiroki Ikeuchi, email: ikeuci2s@hyo-med.ac.jp Keywords: infl...
7. Lower lip cancer managed by reconstruction with a double abbe flap ...
Here, we report a case involving a 78-year-old edentulous woman with lower lip cancer whose resection area involved approximately 70% of the red and white ...
Although the incidence of lower lip cancer is not high in Japan, its treatment requires an approach that considers both esthetics and function. When surgical resection is required, the method used for reconstruction varies depending on the affected part. Despite various studies proposing different types of algorithms, no single method is considered the best. If the loss of half or more of the lip is predicted, a free flap may need to be considered, depending on the case. Here, we report a case involving a 78-year-old edentulous woman with lower lip cancer whose resection area involved approximately 70% of the red and white portions of the lower lip. Fortunately, no resection was required at the commissure. We accordingly performed reconstruction with a double Abbe flap in accordance with a detailed treatment plan. The patient was extremely satisfied with the esthetic and functional outcomes of the surgery.
8. a multicentre prospective cohort study investigating adverse events based ...
We present a protocol of a study that aims to clarify the prevalence of symptom-related adverse events in patients with breast cancer 1 year after neoadjuvant ...
Introduction Symptom-related adverse events associated with perioperative chemotherapy in patients with breast cancer include short-term adverse events such as nausea and vomiting. However, changes in the severity and duration of prolonged symptom-related adverse events have not been fully investigated. We present a protocol of a study that aims to clarify the prevalence of symptom-related adverse events in patients with breast cancer 1 year after neoadjuvant or adjuvant chemotherapy using an electronic patient-reported outcomes (ePRO) system. Methods and analysis This multicentre prospective observational cohort study will include patients with breast cancer who have received preoperative or postoperative adjuvant chemotherapy. The final injection date of the cytotoxic agent will be the study initiation date. Patients will report every 2 weeks from the initiation date to 12 weeks and every 4 weeks from 12 weeks to 1 year, and they can enter this information into the ePRO system from anywhere. The primary outcome will be the prevalence of symptom-related adverse events according to the ePRO system 1 year after the date of the last injection of the cytotoxic drug used in neoadjuvant or adjuvant chemotherapy for breast cancer. To increase multi-institutional enrolment, two cohorts will be included. Cohort 1 will comprise patients with acquisition of baseline patient information regarding preoperative chemotherapy and presurgery characteristics. Cohort 2 will comprise patients...
